Back to Research Home
RDYDr. Reddy’s Laboratories Ltd ADR
Health Care · Biotechnology: Pharmaceutical Preparations · Large
$13.21−0.15%
As of 23 Oct 2026Mkt cap $10.1B
Stage 13
AVOID
Fundamentals
32.6/75
Technical
10.2/15
Independent
42.8/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +7.4%
- 3M
- +12.2%
- 6M
- −3.4%
- 1Y
- −11.2%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 9.3%
- Operating margin
- 22.1%
- FCF margin
- 10.0%
- Current ratio
- 1.8x
Growth
- Revenue growth
- −6.1%Latest FY YoY
- Revenue CAGR
- +6.1%
- EPS CAGR
- −26.4%
- FCF CAGR
- +19.3%
Capital
- Share-count trend
- −0.0%3Y annualised
- Net debt
- $596M1.0x OCF
Annual trend
- CAGR 2022–2026
- +6.1%
- Latest · 2026
- $4B
- YoY
- −6.1%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- early-recovery
- Rotation
- tailwind
- Evidence
- stale
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded